alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]
alpha
RxCUI: 1233711
What the CMS Formulary Data Shows for alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]
Per the CMS 2026 Part D formulary file, alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] (RxNorm concept RXCUI 1233711, generic name alpha) appears on 90 distinct formulary files spanning 886 Medicare Part D plan offerings - 17.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 4.1.
Real-world access to alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] depends on utilization management as much as tier placement: 97.8% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] today.
Coverage Details
- Formularies covering
- 90
- Plans covering
- 886
- Coverage rate
- 17.5%
- Tier range
- Tier 1 – Tier 6
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 97.8% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] covered by Medicare Part D?
Yes, alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] is covered by 886 Medicare Part D plans (17.5% of all Part D formularies).
What tier is alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] on Medicare Part D plans?
alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] averages Tier 4.1 across Part D plans, ranging from Tier 1 to Tier 6.
Does alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] require prior authorization?
97.8% of Part D formularies require prior authorization for alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]. Step therapy: 0%. Quantity limits: 0%.
Read our methodology - how this data is sourced, computed, and verified.